REDWOOD CITY, CA, Ashvattha Therapeutics, a clinical stage company developing novel hydroxyl dendrimer therapeutics, has secured $69 million in a Series B round.
Ashvattha Therapeutics, a clinical stage company developing novel hydroxyl dendrimer therapeutics, has secured $69 million in a Series B financing and in a separate agreement entered an exclusive licensing deal with Huadong Medicine.
The Series B financing was led by Huadong Medicine Investment Holding Co., Ltd, with participation from existing investors, including Natural Capital, Plum Alley, Tribe Capital and several prominent technology and biotech angel investors bringing Ashvattha's total funding to $69 million.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
